litlas
Log inCreate account

David S. Shames

Active 2004–2025

75
Papers
18,163
Citations
61
h-index
72
i10-index

Citations

Citations per year for David S. Shames1971: 1 citations2000: 1 citations2002: 4 citations2004: 2 citations2005: 8 citations2006: 16 citations2007: 45 citations2008: 64 citations2009: 71 citations2010: 87 citations2011: 115 citations2012: 115 citations2013: 151 citations2014: 126 citations2015: 133 citations2016: 188 citations2017: 170 citations2018: 194 citations2019: 747 citations2020: 890 citations2021: 896 citations2022: 835 citations2023: 787 citations2024: 1,140 citations2025: 627 citations2026: 8 citations1972–1999: no citations, so these years are not shown2001: no citations, so this year is not shown2003: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,789 citing papers, 25.3% of this breakdownChina: 1,704 citing papers, 15.5% of this breakdownItaly: 623 citing papers, 5.7% of this breakdownUnited Kingdom: 568 citing papers, 5.2% of this breakdownJapan: 514 citing papers, 4.7% of this breakdownGermany: 511 citing papers, 4.6% of this breakdownFrance: 456 citing papers, 4.1% of this breakdownSpain: 427 citing papers, 3.9% of this breakdownCanada: 329 citing papers, 3% of this breakdownSouth Korea: 270 citing papers, 2.4% of this breakdownSwitzerland: 251 citing papers, 2.3% of this breakdownAustralia: 238 citing papers, 2.2% of this breakdown
0%25.3%Other 21.1%

Institutions

Fields

  • Medicine62.2%
  • Biochemistry, Genetics and Molecular Biology31.7%
  • Immunology and Microbiology3.7%
  • Engineering0.5%
  • Neuroscience0.3%
  • Computer Science0.3%
  • Other1.3%

Topics

  • Cancer Immunotherapy and Biomarkers9.1%
  • Lung Cancer Research Studies8.5%
  • Lung Cancer Treatments and Mutations8.4%
  • Cancer Genomics and Diagnostics6.2%
  • Neuroendocrine Tumor Research Advances3%
  • RNA modifications and cancer2.4%
  • Other62.4%

Coauthors

All papers

Open in search
  1. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

    Authors: Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J. Hochmair, Florian Huemer, György Losonczy, Melissa L. Johnson, Makoto Nishio, Martin Reck, Tony Mok, Sivuonthanh Lam, David S. Shames, Juan Liu, Beiying Ding, Ariel López-Chávez, Fairooz F. Kabbinavar, Wei Lin, Alan Sandler, Stephen V. Liu - New England Journal of Medicine 2018 cited by 3,507

  2. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

    Authors: Carl M. Gay, C. Allison Stewart, Elizabeth M. Park, Lixia Diao, Sarah M. Groves, Simon Heeke, Barzin Y. Nabet, Junya Fujimoto, Luisa M. Solis, Wei Lü, Yuanxin Xi, Robert J. Cardnell, Qi Wang, Giulia Fabbri, Kasey R. Cargill, Natalie I. Vokes, Kavya Ramkumar, Bingnan Zhang, Carminia Maria Della Corte, Paul Robson, Stephen G. Swisher, Jack A. Roth, Bonnie S. Glisson, David S. Shames, Ignacio I. Wistuba, Jing Wang, Vito Quaranta, John D. Minna, John V. Heymach, Lauren A. Byers - Cancer Cell 2021 cited by 932

  3. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

    Authors: Thomas Powles, Zoe J. Assaf, Nicole N. Davarpanah, Romain Banchereau, Bernadett Szabados, Kobe Yuen, Petros Grivas, Maha Hussain, Stéphane Oudard, Jürgen E. Gschwend, Peter Albers, Daniel Castellano, Hiroyuki Nishiyama, Siamak Daneshmand, Shruti Sharma, Bernhard Zimmermann, Himanshu Sethi, Alexey Aleshin, Maurizio Perdicchio, Jingbin Zhang, David S. Shames, Viraj Degaonkar, Xiaodong Shen, Corey Carter, Carlos Bais, Joaquim Bellmunt, Sanjeev Mariathasan - Nature 2021 cited by 629

  4. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

    Authors: Namrata S. Patil, Barzin Y. Nabet, Sören Müller, Hartmut Koeppen, Wei Zou, Jennifer M. Giltnane, Amelia Au‐Yeung, Shyam Srivats, Jason Cheng, Chikara Takahashi, Patrícia E. de Almeida, Avantika S. Chitre, Jane L. Grogan, Linda Rangell, Sangeeta Jayakar, Maureen Peterson, Allison W. Hsia, William O’Gorman, Marcus Ballinger, Romain Banchereau, David S. Shames - Cancer Cell 2022 cited by 403

  5. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

    Authors: David R. Gandara, Sarah Paul, Marcin Kowanetz, Erica Schleifman, Wei Zou, Yan Li, Achim Rittmeyer, Louis Fehrenbacher, Geoff Otto, Christine M. Malboeuf, Daniel S. Lieber, Doron Lipson, Jacob Silterra, Lukas C. Amler, Todd Riehl, Craig Cummings, Priti S. Hegde, Alan Sandler, Marcus Ballinger, David Fabrizio, Tony Mok, David S. Shames - Nature Medicine 2018 cited by 1,195

  6. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

    Authors: Marcelo V. Negrão, Ferdinandos Skoulidis, Meagan Montesion, Katja Schulze, Ilze Bāra, Vincent K. Shen, Hao Xu, Sylvia Hu, Dawen Sui, Yasir Y. Elamin, Xiuning Le, Michael E. Goldberg, Karthikeyan Murugesan, Chang‐Jiun Wu, Jianhua Zhang, Jianhua Zhang, David S Barreto, Jacqulyne Robichaux, Alexandre Reuben, Tina Cascone, Carl M. Gay, K. G. Mitchell, Lingzhi Hong, Waree Rinsurongkawong, Jack A. Roth, Stephen G. Swisher, J. Jack Lee, Anne S. Tsao, Vassiliki A. Papadimitrakopoulou, Don L. Gibbons, Bonnie S. Glisson, Gaurav Singal, Vincent A. Miller, Brian M. Alexander, Garrett M. Frampton, Lee A. Albacker, David S. Shames, Jianjun Zhang, Jianjun Zhang, John V. Heymach - Journal for ImmunoTherapy of Cancer 2021 cited by 292

  7. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

    Authors: Charles M. Rudin, Steffen Durinck, Eric Stawiski, John T. Poirier, Zora Modrušan, David S. Shames, Emily Anne Smith Bergbower, Yinghui Guan, James Shin, Joseph Guillory, Celina Sanchez Rivers, Catherine K. Foo, Deepali Bhatt, Jeremy Stinson, Florian Gnad, Peter M. Haverty, Robert Gentleman, Subhra Chaudhuri, Vasantharajan Janakiraman, Bijay S. Jaiswal, Chaitali Parikh, Wenlin Yuan, Zemin Zhang, Hartmut Koeppen, Thomas D. Wu, Howard M. Stern, Robert L. Yauch, Kenneth E. Huffman, Diego D’Ávila Paskulin, Peter B. Illei, Marileila Varella‐Garcia, Adi F. Gazdar, Frédéric J. de Sauvage, Richard Bourgon, John D. Minna, Malcolm V. Brock, Somasekar Seshagiri - Nature Genetics 2012 cited by 1,098

  8. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade

    Authors: Barzin Y. Nabet, Habib Hamidi, Myung Chang Lee, Romain Banchereau, Stefanie Morris, Leah Adler, Velimir Gayevskiy, Ahmed M. Elhossiny, Minu K. Srivastava, Namrata S. Patil, Kiandra A. Smith, Rajiv Jesudason, Caleb Chan, Patrick Chang, Matthew Fernandez, Sandra Rost, Lisa McGinnis, Hartmut Koeppen, Carl M. Gay, John D. Minna, John V. Heymach, Joseph M. Chan, Charles M. Rudin, Lauren A. Byers, Stephen V. Liu, Martin Reck, David S. Shames - Cancer Cell 2024 cited by 157

  9. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

    Authors: Zoe J. Assaf, Wei Zou, Alexander D. Fine, Mark A. Socinski, Amanda Young, Doron Lipson, Jonathan F. Freidin, Mark Kennedy, Eliana Polisecki, Makoto Nishio, David Fabrizio, Geoffrey R. Oxnard, Craig Cummings, Anja Rode, Martin Reck, Namrata S. Patil, Mark Lee, David S. Shames, Katja Schulze - Nature Medicine 2023 cited by 139

  10. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

    Authors: Jamie E. Chaft, Filiz Öezkan, Mark G. Kris, Paul A. Bunn, Ignacio I. Wistuba, David J. Kwiatkowski, Dwight H. Owen, Yan Tang, Bruce E. Johnson, Jay M. Lee, Gerard Lozanski, Maciej Pietrzak, Michał T. Seweryn, Woo Yul Byun, Katja Schulze, Alan Nicholas, Ann Johnson, Jessica M. Grindheim, Stephanie Hilz, David S. Shames, Chris Rivard, Eric M. Toloza, Eric B. Haura, Ciaran McNamee, G. Alexander Patterson, Saiama N. Waqar, Valerie W. Rusch, David P. Carbone, LCMC study investigators, Saiama N. Waqar, Elaine Shum, Misako Nagasaka, Marianna Koczywas, Edward B. Garon, David J. Finley, David Ross Camidge, Jennifer W. Carlisle, Justin D. Blasberg - Nature Medicine 2022 cited by 237

  11. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

    Authors: Xiangnan Guan, Ruozhen Hu, Yoonha Choi, Shyam Srivats, Barzin Y. Nabet, John Silva, Lisa McGinnis, Robert L. Hendricks, Katherine Nutsch, Karl L. Banta, Ellen Duong, Alexis Dunkle, Patrick Chang, Chia-Jung Han, Stephanie Mittman, Nandini Molden, Pallavi Daggumati, Wendy Connolly, Melissa L. Johnson, Delvys Rodríguez‐Abreu, Byoung Chul Cho, Antoîne Italiano, Ignacio Gil‐Bazo, Enriqueta Felip, Ira Mellman, Sanjeev Mariathasan, David S. Shames, Raymond D. Meng, Eugene Y. Chiang, Robert J. Johnston, Namrata S. Patil - Nature 2024 cited by 123

  12. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

    Authors: Edward S. Kim, Vamsidhar Velcheti, Tarek Mekhail, Cindy Yun, Sarah M. Shagan, Sylvia Hu, Young Kwang Chae, Ticiana Leal, Jonathan E. Dowell, Michaela L. Tsai, Christopher Dakhil, Philip J. Stella, Yanling Jin, David S. Shames, Erica Schleifman, David Fabrizio, See Phan, Mark A. Socinski - Nature Medicine 2022 cited by 170

  13. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

    Authors: Howard West, Mark L. McCleland, Federico Cappuzzo, Martin Reck, Tony Mok, Robert M. Jotte, Makoto Nishio, Eugene Kim, Stefanie Morris, Wei Zou, David S. Shames, Meghna Das Thakur, Geetha Shankar, Mark A. Socinski - Journal for ImmunoTherapy of Cancer 2022 cited by 151

  14. Molecular determinants of response to PD-L1 blockade across tumor types

    Authors: Romain Banchereau, Ning Leng, Oliver A. Zill, Ethan S. Sokol, Gengbo Liu, Dean Pavlick, Sophia L. Maund, Lifen Liu, Edward E. Kadel, Nicole Baldwin, Suchit Jhunjhunwala, Dorothee Nickles, Zoe J. Assaf, Daniel Bower, Namrata S. Patil, Mark L. McCleland, David S. Shames, Luciana Molinero, Mahrukh Huseni, Shomyseh Sanjabi, Craig Cummings, Ira Mellman, Sanjeev Mariathasan, Priti S. Hegde, Thomas Powles - Nature Communications 2021 cited by 171

  15. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

    Authors: Solange Peters, Rafał Dziadziuszko, Alessandro Morabito, Enriqueta Felip, Shirish M. Gadgeel, Parneet Cheema, Manuel Cobo, Zoran Andrić, Carlos H. Barrios, Masafumi Yamaguchi, Éric Dansin, Pongwut Danchaivijitr, Melissa L. Johnson, Silvia Novello, Michael S. Mathisen, Sarah M. Shagan, Erica Schleifman, Jin Wang, Mark Yan, Simonetta Mocci, David Voong, David Fabrizio, David S. Shames, Todd Riehl, David R. Gandara, Tony Mok - Nature Medicine 2022 cited by 111

  16. Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma

    Authors: Manish A. Shah, Yung‐Jue Bang, Florian Lordick, María Alsina, Meng Chen, Stephen P. Hack, Jean Marie Bruey, Dustin Smith, Ian McCaffery, David S. Shames, See Phan, David Cunningham - JAMA Oncology 2016 cited by 301

  17. Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells

    Authors: Pei-Hsuan Chen, Ling Cai, Kenneth E. Huffman, Chendong Yang, Jiyeon Kim, Brandon Faubert, Lindsey K. Boroughs, Bookyung Ko, Jessica Sudderth, Elizabeth A. McMillan, Luc Girard, Dong Chen, Michael Peyton, Misty Dawn Shields, Bo Yao, David S. Shames, Hyun Seok Kim, Brenda C. Timmons, Ikuo Sekine, Rebecca Britt, Stephanie Weber, Lauren A. Byers, John V. Heymach, Jing Chen, Michael A. White, John D. Minna, Guanghua Xiao, Ralph J. DeBerardinis - Molecular Cell 2019 cited by 231

  18. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung

    Authors: David R. Spigel, Martin J. Edelman, Kenneth J. O’Byrne, Luis Paz‐Ares, Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, Virginia Paton, Tony Mok - Journal of Clinical Oncology 2017 cited by 326

  19. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib

    Authors: Triparna Sen, Pan Tong, C. Allison Stewart, Sandra Cristea, Aly Valliani, David S. Shames, Abena B. Redwood, You Hong Fan, Lerong Li, Bonnie S. Glisson, John D. Minna, Julien Sage, Don L. Gibbons, Helen Piwnica‐Worms, John V. Heymach, Jing Wang, Lauren A. Byers - Cancer Research 2017 cited by 195

  20. Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

    Authors: Bruna Pellini, Russell W. Madison, Merrida Childress, Shoshana T. Miller, Ole Gjoerup, Jason Cheng, Richard S.P. Huang, Michael Krainock, Pratyush Gupta, Wei Zou, David S. Shames, Solomon Moshkevich, M. Ballinger, Minetta C. Liu, Amanda Young, Minu K. Srivastava, Geoffrey R. Oxnard, Mark A. Socinski - Clinical Cancer Research 2023 cited by 45

  21. Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study

    Authors: Claire F. Friedman, John D. Hainsworth, Razelle Kurzrock, David R. Spigel, Howard A. Burris, Christopher J. Sweeney, Funda Meric‐Bernstam, Yong Wang, Jonathan Levy, Jessica M. Grindheim, David S. Shames, Katja Schulze, Arisha Patel, Charles Swanton - Cancer Discovery 2021 cited by 101

  22. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

    Authors: Marcin Kowanetz, Wei Zou, Scott Gettinger, Hartmut Koeppen, Mark Kockx, Peter Schmid, Edward E. Kadel, Ignacio I. Wistuba, Jamie E. Chaft, Naiyer A. Rizvi, David R. Spigel, Alexander I. Spira, Fred R. Hirsch, Victor Cohen, Dustin Smith, Zach Boyd, Natasha Miley, Susan Flynn, Vincent Lévêque, David S. Shames, Marcus Ballinger, Simonetta Mocci, Geetha Shankar, Roel Funke, Garret M. Hampton, Alan Sandler, Lukas C. Amler, Ira Mellman, Daniel S. Chen, Priti S. Hegde - National Academy of Sciences, Proceedings of the National Academy of Sciences 2018 cited by 239

  23. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer

    Authors: Ling Cai, Hongyu Liu, Fang Huang, Junya Fujimoto, Luc Girard, Jun Chen, Li Y, Yu‐An Zhang, Dhruba Deb, Victor Stastny, Karine Pozo, Christin S. Kuo, Gaoxiang Jia, Chendong Yang, Wei Zou, Adeeb Alomar, Kenneth E. Huffman, Mahboubeh Papari-Zareei, Lin Yang, Benjamin J. Drapkin, Esra A. Akbay, David S. Shames, Ignacio I. Wistuba, Tao Wang, Jane E. Johnson, Guanghua Xiao, Ralph J. DeBerardinis, John D. Minna, Yang Xie, Adi F. Gazdar - Communications Biology 2021 cited by 101

  24. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

    Authors: Tony Mok, Yi‐Long Wu, Jin Soo Lee, Chong‐Jen Yu, Virote Sriuranpong, Jennifer Sandoval-Tan, Guia Ladrera, Sumitra Thongprasert, Vichien Srimuninnimit, Meilin Liao, Yunzhong Zhu, Caicun Zhou, Fatima Fuerte, Benjamin Margono, Wei Wen, Julie Tsai, Matt Truman, Barbara Klughammer, David S. Shames, Lin Wu - Clinical Cancer Research 2015 cited by 469